Stay updated on Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial
Sign up to get notified when there's something new on the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page.

Latest updates to the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s revision tag was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. No visible changes to the study details or eligibility criteria.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page shows a minor version update from v3.4.1 to v3.4.2. This change does not affect the study details or how users interact with the page.SummaryDifference0.0%

- Check60 days agoChange DetectedThe update is a site version change from v3.4.0 to v3.4.1; there are no changes to the study content, eligibility, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check81 days agoChange DetectedThe revision tag changes from v3.3.3 to v3.3.4; there are no visible changes to the study details page.SummaryDifference0.0%

- Check103 days agoChange DetectedLocations and affiliated centers updated: new sites in California, Massachusetts, New Mexico, Oregon, and Texas, plus UT Southwestern Medical Center added; some listings removed, and the page revision updated to v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page.